Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 2, 1998, Pages 104-111

  Choudhury, Indrani ^a   Wang, Jihong ^b,c   Rabson, Arnold B ^a,b,d   Stein, Steven ^b   Pooyan, Shahriar ^a,b   Stein, Stanley ^a,b,c,d   Leibowitz, Michael J ^a,d  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Ctr for Adv Biotech and Medicine

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Biotin; HIV 1 inhibition; TAR; Tat; Tat mimic; Therapeutic agent

Indexed keywords

ANTIVIRUS AGENT; BIOTIN; N ACETYL ARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLCYSTIENE (BIOTIN) AMIDE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL TRANSPORT; DRUG UPTAKE; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN RNA BINDING; REPORTER GENE; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0032005403     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802010-00002     Document Type: Article

References (43)

1. Cullen BR. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 1992;56:375-94.
2. Jones KA, Peterlin BM. Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994;63:717-43.
3. Gaynor RB. Regulation of HIV-1 gene expression by the transactivator protein Tat. Curr Top Microbiol Immunol 1995;193:51-77.
4. Fisher AG, Feinberg MB, Josephs SF, et al. The trans-activator of HTLV-III is essential for virus replication. Nature 1986;320:367-71.
5. Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 1986;44:941-7.
6. Harrich D, Hsu C, Race E, Gaynor RB. Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants. J Virol 1994;68:5899-910.
7. Feinberg MB, Baltimore D, Frankel AD. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA 1991; 88:4045-9.
8. Cupelli LA, Hsu M-C. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J Virol 1995;69:2640-3.
9. Farese A, Peytou V, Condom R, et al. Synthesis of analogues of the benzodiazepine Ro 5-3335, antagonist of Tat HIV-1. Biological evaluation by luciferase transactivation and anti-viral assay. Eur J Med Chem 1996;31:497-505.
10. Lapidot A, Ben-Asher E, Eisenstein M. Tetrahydropyrimidine derivatives inhibit binding of a Tat-like arginine-containing peptide to HIV TAR RNA. FEBS Lett 1995;367:33-8.
11. McMillan NAJ, Chun RF, Siderovski DP, et al. HIV-1 Tat directly interacts with the interferon-induced double-stranded RNA-dependent kinase, PKR. Virology 1995;213:413-24.
12. Brady HJM, Abraham DJ, Pennington DJ, Miles CG, Jenkins S, Dzierzak EA. Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice. J Virol 1995; 69:7622-9.
13. Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995;268:429-31.
14. Re MC, Furlini G, Vignoli M, et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Synr Human Retrovirol 1995;10:408-16.
15. Hauber J, Cullen BR. Mutational analysis of the transactivation-responsive region of the human immunodeficiency virus type 1 long terminal repeat. J Virol 1988;62:673-9.
16. Jacobovits D, Smith H, Jakobovits EB, Capon DJ. A discrete element 3′ of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator. Mol Cell Biol 1988;8:2555-61.
17. Dingwall C, Ernberg I, Gait MJ, et al. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci USA 1989;86:6925-9.
18. Cordingly MG, Lafemina RL, Callahan PL, et al. Sequence specific interaction of Tat protein and Tat peptides with the transactivation-response sequence element of human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA 1990;87:8985-9.
19. Roy S, Delling U, Cher CH, Rosen CA, Sonenberg N. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev 1990;4:1365-73.
20. Weeks KM, Ampe C, Schultz SC, Steitz TA, Crothers DM. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 1990;249:1281-5.
21. Marciniak RA, Garcia-Blanco MA, Sharp PA. Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus. Proc Natl Acad Sci USA 1990;87:3624-8.
22. Sheline CT, Milocco LH, Jones KA. Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin. Genes Dev 1991;5:2508-20.
23. Wu F, Garcia J, Sigman D, Gaynor R. Tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes Dev 1991;5:2128-40.
24. Gatignol A, Buckler-White A, Berkhout B, Jeang KT. Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science 1991;251:1597-600.
25. Shibuya H, Irie K, Ninomiya-Tsuji J, Goebl M, Taniguchi T, Matsumoto K. New human gene encoding a positive modulator of HIV tat-mediated transactivation. Nature 1992;358:700-2.
26. Desai K, Loewenstein PM, Green M. Isolation of a cellular protein that binds to the human immunodeficiency virus tat protein and can potentiate transactivation of the viral promoter. Proc Natl Acad Sci USA 1991;88:8875-9.
27. Ohana B, Moore PA, Ruben SM, Southgate D, Green ME, Rosen CA. The type 1 human immunodeficiency virus Tat binding protein is a transcriptional activator belonging to an additional family of evolutionarily conserved genes. Proc Natl Acad Sci USA 1993; 90:138-42.
28. Herrmann CR, Rice AP. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK. that hyperphosphorylates the carboxy-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol 1995;69:1612-20.
29. Mavankal G, Ou SHI, Oliver H, Sigman D, Gaynor RB. Human immunodeficiency virus type 1 and 2 Tat proteins specifically interact with RNA polymerase II. Proc Natl Acad Sci USA 1996; 93:2089-94.
30. Antoni BA, Stein SB, Rabson AB. Regulation of human immunodeficiency virus infection: implications for pathogenesis. In: Mamarosch K, Murphy FA, Shatkin AJ, eds. Advances in virus research. New York: Academic Press, 1994;43:53-145.
31. Tung C-H, Wang J, Leibowitz MJ, Stein S. Dual specificity interactions of HIV-1 TAR RNA with Tat peptide-oligonucleotide conjugates. Bioconj Chem 1995;6:292-5.
32. Wang J, Huang S-Y, Choudhury I, Leibowitz MJ, Stein S. Use of a polyethylene glycol-peptide conjugate in a competition gel shift assay for screening potential antagonists of HIV-1 Tat protein binding to TAR RNA. Anal Biochem 1995;232:238-42.
33. Dyer RB, Herzog NK. Isolation of intact nuclei for nuclear extract preparation from a fragile B-lymphocyte cell line. BioTechniques 1995;19:192-4.
34. Gendelman HE, Phelps W, Feigenbaum L, et al. Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci USA 1986;83:9759-63.
35. Dorset DL, Keshet I, Winocour E. Quantitation of a simian virus 40 nonhomologous recombination pathway. J Virol 1983;48:218-28.
36. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods 1986;93:157-65.
37. Willey RL, Smith DH, Lasky LA, et al. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 1988;62:139-47.
38. Chen LL, Frankel AD, Harder JL, Fawell S, Barsoum J, Pepinsky B. Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin. Anal Biochem 1995;227:168-75.
39. O'Brien WA, Sumner-Smith M, Mao S-H, Sadeghi S, Zhao J-G, Chen IS. Anti-human immunodeficiency virus type I activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol 1996;70:2825-31.
40. Cullen BR. Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 1986;46:973-82.
41. Brother MB, Chang H-K, Lisziewicz J, Su D, Murty LC, Ensoli B. Block of Tat-mediated transactivation of tumor necrosis factor β gene expression by polymeric-TAR decoys. Virology 1996;222: 252-6.
42. Hamy F, Felder ER, Heizmann G, et al. An inhibitor of the Tat/ TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 1997;94:3548-53.
43. Kashanchi F, Reza M, Brady JN. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs. Virology 1997;227:431-8.